Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Mutant Huntingtin and Neurofilament Light Valid Biomarkers in Huntington’s Disease

Publish date:: July 16, 2019

Key clinical point: Mutant huntingtin and plasma and cerebrospinal fluid levels of neurofilament light are useful biomarkers in Huntington’s disease.

Major finding: Levels of neurofilament light in plasma are correlated with those in cerebrospinal fluid.

Study details: A prospective, observational cohort study including 80 participants with and without Huntington’s disease.

Disclosures: No funding for this study was reported.

Citation:

Rodrigues FB et al. AAN 2019, Abstract S16.003.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Huntington's Disease

Mutant Huntingtin and Neurofilament Light Valid Biomarkers in Huntington’s Disease,

Genetic Therapy Reduces Key Protein in Huntington’s Disease,